TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Inventiva ( (IVA) ) has provided an update.
On November 12, 2025, Inventiva S.A. entered into an underwriting agreement with Leerink Partners LLC and Piper Sandler & Co. for a public offering of 38,961,038 American Depositary Shares (ADSs) at $3.85 per ADS. The offering is expected to raise approximately $140.1 million, with a potential increase to $161.2 million if the underwriters exercise their option to purchase additional ADSs. The offering, which is anticipated to close on November 17, 2025, is part of Inventiva’s strategy to strengthen its financial position and support its ongoing research and development efforts.
The most recent analyst rating on (IVA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Inventiva stock, see the IVA Stock Forecast page.
Spark’s Take on IVA Stock
According to Spark, TipRanks’ AI Analyst, IVA is a Neutral.
Inventiva’s overall stock score is primarily impacted by its poor financial performance, characterized by persistent losses and negative margins. The technical analysis further indicates a bearish trend, while the valuation metrics highlight ongoing financial challenges. The absence of earnings call data and corporate events does not influence the score.
To see Spark’s full report on IVA stock, click here.
More about Inventiva
Inventiva S.A. is a French company operating in the biotechnology industry, focusing on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidosis (MPS), and other diseases with significant unmet medical needs.
Average Trading Volume: 193,160
Technical Sentiment Signal: Buy
Current Market Cap: $565.6M
Find detailed analytics on IVA stock on TipRanks’ Stock Analysis page.